### Thursday, October 27, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Event</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30-14:35</td>
<td>Welcome</td>
<td>Tony R. Green (Cambridge)</td>
</tr>
<tr>
<td>14:35-16:10</td>
<td>SESSION I – Genetic and Cellular Pathogenesis of MPNs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Tony R. Green</td>
<td></td>
</tr>
<tr>
<td>14:35-14:50</td>
<td>Genetic basis of myelodysplastic/myeloproliferative neoplasms</td>
<td>Mario Cazzola (Pavia)</td>
</tr>
<tr>
<td>14:50-15:05</td>
<td>Causes of myeloproliferative disorders</td>
<td>Mary-Frances McMullin (Belfast)</td>
</tr>
<tr>
<td>15:05-15:20</td>
<td>Novel oncogenic mechanisms in myeloproliferative neoplasms: the mutated</td>
<td>Stefan Constantinescu (Brussels)</td>
</tr>
<tr>
<td></td>
<td>chaperon calreticulin embracing cytokine receptors</td>
<td></td>
</tr>
<tr>
<td>15:20-15:35</td>
<td>The genomic basis of acute lymphoblastic leukaemia</td>
<td>Charles G. Mullighan (Memphis)</td>
</tr>
<tr>
<td>15:35-15:50</td>
<td>The genomics of MPNs</td>
<td>Peter Campbell (Cambridge)</td>
</tr>
<tr>
<td>15:50-16:00</td>
<td>Mutant JAK2 expression and erythroid-platelet lineage decisions: genotype-</td>
<td>Tata Nageswara Rao</td>
</tr>
<tr>
<td></td>
<td>phenotype correlations in MPN</td>
<td></td>
</tr>
<tr>
<td>16:00-16:10</td>
<td>Endothelial cells are important players in the pathogenesis of thrombosis</td>
<td>Alexandre Guy</td>
</tr>
<tr>
<td></td>
<td>in myeloproliferative neoplasms</td>
<td></td>
</tr>
<tr>
<td>16:10-16:40</td>
<td>Round Table</td>
<td></td>
</tr>
<tr>
<td>16:40</td>
<td>Tutored poster walk</td>
<td>Richard Silver (New York)</td>
</tr>
<tr>
<td></td>
<td>(Authors to be in front of their posters)</td>
<td>TBA*</td>
</tr>
<tr>
<td></td>
<td>Get-together finger food dinner reception</td>
<td></td>
</tr>
</tbody>
</table>
### SESSION II – Novel MPN Therapeutics  
**Chair:** Radek Skoda

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-08:45</td>
<td>Epigenetic alterations and therapeutic targeting in MPN</td>
<td>Ross L. Levine (New York)</td>
</tr>
<tr>
<td>08:45-09:00</td>
<td>Role of megakaryocytes in the MPNs</td>
<td>John D. Crispino (Chicago)</td>
</tr>
<tr>
<td>09:00-09:15</td>
<td>Molecular insights into regulation of JAK2 in MPN</td>
<td>Olli Silvennoinen (Tampere)</td>
</tr>
<tr>
<td>09:15-09:30</td>
<td>Using molecular information to inform patient management</td>
<td>Alessandro M. Vannucchi (Florence)</td>
</tr>
<tr>
<td>09:30-09:45</td>
<td>Targeting JAK2 – Have we arrived?</td>
<td>Thomas Radimerski (Basel)</td>
</tr>
<tr>
<td>09:45-09:55</td>
<td>Effectiveness of LSD1 inhibition for the treatment of MPN</td>
<td>Jonas Jutzi</td>
</tr>
<tr>
<td>09:55-10:05</td>
<td>Synergistic therapeutic efficacy of combined JAK1/2, Pan-PIM, and CDK4/6 inhibition in MPN</td>
<td>Raajit Rampal</td>
</tr>
</tbody>
</table>

#### 10:05-10:35  
**Round Table**

#### 10:35-11:05  
**Coffee break**

### SESSION III – Mechanisms of Myeloid Transformation and Progression  
**Chair:** William Vainchenker

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:05-11:20</td>
<td>Cellular and molecular response to interferon therapy in PV and ET</td>
<td>Josef Prchal (Salt Lake City)</td>
</tr>
<tr>
<td>11:20-11:35</td>
<td>Functional and molecular dissection of molecular drivers in MPN</td>
<td>Ann Mullally (Boston)</td>
</tr>
<tr>
<td>11:35-11:50</td>
<td>MPN pathogenesis &amp; JAK/STAT signalling</td>
<td>Tony R. Green (Cambridge)</td>
</tr>
<tr>
<td>11:50-12:05</td>
<td>Bone marrow niches for HSCs in MPN</td>
<td>Simón Méndez-Ferrer (Cambridge)</td>
</tr>
<tr>
<td>12:05-12:20</td>
<td>What is new about the pathogenesis of thrombosis in MPN in 2016?</td>
<td>Chloé James (Bordeaux)</td>
</tr>
<tr>
<td>12:20-12:30</td>
<td>The MEK/ERK inhibitor trametinib reduces fibrosis in a transduction-transplantation model of mutated calreticulin</td>
<td>Angela Fleischman</td>
</tr>
</tbody>
</table>

#### 12:30-13:00  
**Round Table**

#### 13:00-14:30  
**Lunch and posters**

### SESSION IV – Murine Modeling of MPN  
**Chair:** Ross L. Levine

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30-14:45</td>
<td>Stem cell origin of myeloproliferative neoplasms</td>
<td>Radek Skoda (Basel)</td>
</tr>
</tbody>
</table>
14:45-15:00  Modeling predisposition to familial MPN  
            Isabelle Plo (Villejuif)

15:00-15:15  Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms  
            Heike L. Pahl (Freiburg)

15:15-15:30  Modeling the calreticulin disease in mice  
            William Vainchenker (Villejuif)

15:30-15:40  Potential for the JAK/STAT pathway inhibitor methotrexate in MPNs  
            Martin Zeidler*

15:40-15:50  HSC genetic heterogeneity determines clonal dynamics in PMF  
            Ioanna Triviat*  

15:50-16:20  Round Table

16:20-16:45  Coffee Break

16:45-18:45  Satellite Symposium  
            Chairperson: TBA  
            Faculty: TBA
            This activity is provided by prIME Oncology.  
            This educational activity is supported by a grant from Novartis Oncology

20:00  Faculty Dinner

Saturday, October 29, 2016

08:00-09:00  4 simultaneous meet the expert sessions:  
            1. Alessandro M. Vannucchi (Florence)  
            2. Ruben A. Mesa (Scottsdale)  
            3. Claire Harrison (London)  
            4. Ross L. Levine (New York)

SESSION V – Targeting the MPN Stem Cell  
            Chair: Alessandro M. Vannucchi

09:00-09:15  RNA rewriting, recoding and rewiring in myeloproliferative neoplasms stem cells  
            Catriona Jamieson (La Jolla)

09:15-09:30  Optimize transplant results in myelofibrosis  
            Nicolaus Kröger (Hamburg)

09:30-09:45  Using single cell biology to identify stem cell fate regulators in haematological malignancies  
            David Kent (Cambridge)

09:45-10:00  The effects of specialized microenvironments on haematopoiesis in myelofibrosis  
            Ronald Hoffman (New York)

10:00-10:10  The Calr Exon 9 mutations may be promising targets for cancer immune therapy in the Calr Exon 9 mutated chronic myeloproliferative neoplasms  
            Morten Orebo Holmström

10:10-10:20  Interferon alpha (IFNa) targets differentially hematopoietic stem cells and mature cells in JAK2V617F, Calr and MPLW515K patients with myeloproliferative neoplasms  
            Matthieu Mosca*
10:20-10:50  
*Round Table*

10:50-11:20  
*Coffee Break*

**SESSION VI – Recent Advances in Management**

**Chair:** Tiziano Barbui

11:20-11:35  
Natural history and risk stratification of prefibrotic myelofibrosis  
Giovanni Barosi (Pavia)

11:35-11:50  
TBA*  
TBA*

11:50-12:05  
An update of interferon trials in MPN  
Jean-Jacques Kiladjian (Paris)

12:05-12:20  
*Rethink: a phase 3 study of ruxolitinib in patients with early myelofibrosis having at least 1 high molecular risk mutation*  
Francesco Passamonti*

12:20-12:30  
*Raptor is essential both for development of MPN and for normal hematopoiesis*  
Takafumi Shimizu

12:30-12:40  
*Monitoring of calreticulin mutations and hematopoietic chimerism by digital PCR after allogeneic stem cell transplantation in patients with myelofibrosis*  
Anita Badbaran*

12:40-13:10  
*Round Table*

13:10-14:40  
*Lunch and posters*

**SESSION VII – Recent Advances in Management 2**

**Chair:** Heike L. Pahl

14:40-14:55  
Rethinking the treatment recommendations in low-risk PV  
Tiziano Barbui (Bergamo)

14:55-15:10  
Next generation MPN management  
Ruben A. Mesa (Scottsdale)

15:10-15:25  
Promises and pitfalls of JAK inhibitor therapy  
Claire Harrison (London)

15:25-15:55  
*Round Table*

15:55-16:05  
Closing remarks

**MEETING CLOSURE**

*To be confirmed*